 MALVERN, Pa., Nov. 21, 2022 GLOBE NEWSWIRE -- Neuronetics, Inc. NASDAQ:STIM, a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Companys website at ir.neuronetics.com . A replay of the webcast will be archived on the website for approximately 90 days. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasnt helped. NeuroStar is FDA-cleared for adults with major depressive disorder MDD, as an adjunct for adults with obsessive-compulsive disorder OCD, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms anxious depression. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation TMS treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the worlds largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, Investor Contact: Mark KlausnerWestwicke Partners443-213-0501 Media Contact: EvolveMKD646.517.4220 